1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. Class A

Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. Class A

SSZSE:002223
27.31
CNY
+1.73
(+6.76%)
1.45EPS
17.81P/E
25.72BMarket Cap
Apr 26Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.64
1.93
2.39
2.8
3.53
4.2
4.62
6.69
6.93
7.17
8.02
7.58
7.95
8.23
Basic EPS, GAAP
0.3
0.34
0.41
0.53
0.59
0.73
0.75
1.75
1.49
1.61
2.41
1.81
1.48
1.44
Free Cash Flow per Basic Share
0.04
0.07
0.43
0.63
-0.25
0.41
0.17
2.14
0.92
1.94
2.01
1.69
1.37
- -
Dividend per Share
0.06
0.06
0.01
0.25
0.27
0.16
0.16
0.41
0.32
0.35
0.66
1.23
0.8
0.4
Book Value per Share
1.72
2
2.41
4.9
5.23
5.45
6.06
7.42
8.25
9.84
11.73
12.5
13.21
13.3
Tangible Book Value per Share
1.62
1.89
1.84
4.41
3.88
4.12
4.73
6.06
6.51
8.21
10.12
10.93
11.67
11.79
Basic Weighted Avg Shares
869
874
881
943
1,003
996
1,003
1,005
995
991
994
998
1,001
997
Sales/Revenue/Turnover
1,424
1,682
2,104
2,640
3,542
4,183
4,636
6,726
6,894
7,102
7,972
7,566
7,955
8,203
Operating Margin (%)
18.09
17.54
18.07
19.28
18.53
17.31
17.96
30.31
23.34
21.97
26.66
22.92
18.85
17.72
Depreciation Expense
29
36
52
62
80
91
96
161
202
222
232
252
265
- -
Net Income, GAAP
258
297
364
500
592
727
753
1,759
1,482
1,595
2,396
1,806
1,482
1,437
Effective Tax Rate (%)
13.28
10.73
10.08
12.4
12.87
11.23
11.89
12.98
12.8
14.64
16.58
6.65
11.89
11.07
Profit Margin (%)
18.12
17.66
17.32
18.93
16.72
17.38
16.23
26.15
21.5
22.46
30.05
23.87
18.63
17.51
Working Capital
1,012
1,246
1,124
3,998
3,282
2,769
2,586
2,994
5,034
6,687
6,512
6,566
1,339
5,574
LT Debt
20
20
- -
50
- -
- -
- -
15
1,475
1,540
713
20
14
4
Total Equity
1,517
1,762
2,132
4,935
5,571
5,545
6,157
7,495
8,430
10,066
11,915
12,654
13,355
13,450
Return on Invested Capital (%)
15.41
15.26
16.43
12.95
11.12
12.12
12.53
24.22
16.24
14.05
18.81
13.82
11.42
10.62
Return on Capital (%)
18.06
17.7
17.81
13.67
10.43
12.37
12.5
24.53
16.65
15.06
19.45
14.13
11.38
10.7
Return on Common Equity (%)
18.38
18.24
18.85
14.22
11.66
13.58
13.04
26.04
18.87
17.59
22.16
14.86
11.5
10.87

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
24
17
22
LT Borrowings
- -
- -
- -
LT Finance Leases
14
16
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,002
1,002
1,002
Market Capitalization
38,305
33,984
25,724

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
3,797
6,634
8,744
Cash, Cash Equivalents & STI
579
943
1,379
Accounts Receivable, Net
709
1,255
1,260
Inventories
1,478
1,228
1,329
Total Current Liabilities
2,459
2,826
3,170
Payables & Accruals
- -
- -
- -
ST Debt
24
17
22
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
23.86%
12.4%
5.54%
Free Cash Flow
75.46%
4.45%
-18.6%
Net Income, GAAP
21.52%
-0.1%
-17.94%
Sales/Revenue/Turnover
15.15%
3.56%
5.14%
Total Cash Common Dividend
248.75%
25.15%
-34.75%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,231
2,076
1,720
1,538
7,566
2025
2,436
2,223
- -
1,410
7,955
2026
2,370
2,199
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.66
0.46
0.41
0.27
1.81
2025
0.63
0.58
- -
0.02
1.48
2026
0.43
0.42
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.8
- -
0.41
1.23
2025
- -
- -
- -
0.4
0.8
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Qun Wu
Full Time Employees
8,294
Sector
Health technology
Industry
Medical specialties
Address
No. 1 Baisheng Road, Development Zone Zhenjiang JS China 212300
IPO Date
Apr 18, 2008
Website
yuyue.com.cn
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. engages in the research, development, manufacturing, and sale of home medical devices, clinical medical products, and related health management services primarily in China and internationally. The company offers a comprehensive portfolio of products including respiratory solutions such as single-level and bi-level positive airway pressure (PAP) devices, oxygen concentrators, nebulizers, high-flow nasal cannula oxygen therapy systems, suction apparatus, and airway clearance devices; diabetes management products like continuous glucose monitoring systems and blood glucose meters; blood pressure monitoring systems comprising electronic sphygmomanometers; diagnostic tools including infrared thermometers, digital thermometers, oximeters, and pulse oximeters; and rehabilitation equipment such as wheelchairs and electric wheelchairs. It operates through segments focused on respiratory therapy, diabetes care, infection control, home testing, and rehabilitation nursing, serving hospitals, clinics, and home care users across domestic and export markets in over 100 countries. Founded in 1998 and headquartered in Yancheng, Jiangsu Province, the company maintains multiple manufacturing centers in China, including sites in Jiangsu, Chongqing, and Guangdong, alongside 12 research and development centers and nine production facilities globally. Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. lists on the Shenzhen Stock Exchange under ticker 002223.SZ since 2010 and has expanded through strategic moves such as forming the Yuwell Group, acquiring CR Group's medical device division, establishing a German subsidiary and Jinzhong R&D center, acquiring Shanghai Zhongyou Medical and full equity in German PARI (Pruemmelkon), gaining stakes in Menno and Yunnan Baiyao, taking control of Italian BVS, launching the Yiyun Health APP, enabling its Tibet subsidiary and Global Life Science Industrial Park, participating in Jiangsu Shizhun, and acquiring 66 Visual. In recent developments, it announced a strategic investment and partnership with U.S.-based Inogen in January 2025 to collaborate on respiratory health through international distribution, trademark licensing, joint R&D, and supply chain optimization, alongside advancing overseas expansion, AI-powered wearable devices, and robust growth in blood glucose and respiratory segments as of Q3 2025.